OTS514

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

OTS514 是一种有效的 TOPK 抑制剂。 OTS514 对小细胞肺癌具有生长抑制作用。 OTS514有效抑制SCLC细胞系的生长（IC50：0.4 ~ 42.6 nM）。

OTS514 is a potent TOPK inhibitor. OTS514 exhibits a growth-suppressive effect on small cell lung cancer. OTS514 effectively suppressed the growth of SCLC cell lines (IC50: 0.4 ~ 42.6 nM). Treatment with OTS514 suppressed forkhead box protein M1 (FOXM1) activity. OTS514 treatment reduced CD90-positive SCLC cells and showed a higher cytotoxic effect against lung sphere-derived CSC-like SCLC cells.

OTS514 (1.5625-100 nM) induces cell cycle arrest and apoptosis at nanomolar concentrations in a series of human myeloma cell lines (HMCL) and prevents outgrowth of a putative CD138+ stem cell population from multiple myeloma (MM) patient-derived peripheral blood mononuclear cells.Cell Viability Assay Cell Line:Human myeloma cell lines (MM1.S, MM1.R, RPMI 8226, 8226Dox40, KMS34, KMS34CFZ, KMS11, JJN3, LP-1, NCI H929, U266B1)Concentration:1.5625, 3.125, 6.25, 12.5, 25, 50, and 100 nM Incubation Time:72 hours Result:IC50 values ranged from 11.6 to 29.4 nM in parental cell lines, indicating a potent inhibitory effect. Only the RPMI 8226-Dox40 cell line, which overexpresses the multi-drug resistance transporter gene ABCB1, is resistant.

OTS514 (1-5 mg/kg; once a day for 2 weeks; intravenous administration) induces tumor regression in a xenograft model of A549 cells (TOPK-positive lung cancer cells). Animal Model:Female BALB/cSLC-nu/nu mice bearing a xenograft model of A549 cells Dosage:1, 2.5, and 5 mg/kg Administration:Intravenously treated; once every day for 2 weeks Result:Resulted in tumor growth inhibition (TGI) of 5.7, 43.3, and 65.3% on day 15, respectively, without any body weight loss.

OTS514 | OTS 514 | OTS-514 | OTS514 Hydrochloride

Others

Other Targets

TOPK

——

——

1338540-63-8

364.46

C21H20N2O2S

>98% (HPLC)

DMSO:90 mg/mL?(246.94 mM;?Need ultrasonic)

CC(CN)c(cc1)ccc1-c(c(-c1c2scc1)c(c(C)c1)NC2=O)c1O

——

(-20℃)

With Ice Pack

≥ 2 years